The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity
USP17LA loss enhances T-cell function and anti-tumor activity in murine tumor models. Usp17la-deficient T cells exhibit ...
13h
Made Scientific and Syenex Forge Technology Partnership to Transform T Cell Therapy Manufacturing
Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company specializing in best-in-class targeted delivery technologies, ...
SciTech Development, Inc., a clinical-stage oncology company advancing its innovative nanotechnology-enabled cancer drug, ...
SciTech Development Inc., a clinical-stage oncology company in Detroit, has closed its Convertible Note Round No. 3 (CNR 3) ...
Dr Maja Petkovic commented “The first FDA approved treatments were CAR-T cells directed against the B cell protein CD19. This ...
Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...
Researchers at the University of Granada and Mount Sinai Hospital in New York have developed a luminescent probe, called GLed ...
UCSF researchers designed a CAR T-cell therapy and combined it with an older class of diabetes drugs called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback